SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer  by Li, Lianjie et al.
Cancer Cell
ArticleSQSTM1 Is a Pathogenic Target
of 5q Copy Number Gains in Kidney Cancer
Lianjie Li,1 Chuan Shen,1 Eijiro Nakamura,1 Kiyohiro Ando,1 Sabina Signoretti,1,3 Rameen Beroukhim,1,2,4,5
Glenn S. Cowley,5 Patrick Lizotte,5 Ella Liberzon,1,11 Steven Bair,1 David E. Root,5 Pablo Tamayo,5 Aviad Tsherniak,5
Su-Chun Cheng,6 Barbara Tabak,2,5 Anders Jacobsen,7 A. Ari Hakimi,8 Nikolaus Schultz,7 Giovanni Ciriello,7
Chris Sander,7 James J. Hsieh,9,10 and William G. Kaelin, Jr.1,4,5,11,*
1Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston,
MA 02115, USA
2Department of Cancer Biology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston,
MA 02115, USA
3Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
4Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
5Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
6Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
7Department of Computational Biology, Memorial Sloan-Kettering Cancer Center, New York, NY 16605, USA
8Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 16605, USA
9Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 16605, USA
10Department of Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 16605, USA
11Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
*Correspondence: william_kaelin@dfci.harvard.edu
http://dx.doi.org/10.1016/j.ccr.2013.10.025SUMMARYClear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer and is often linked to loss
of chromosome 3p, which harbors the VHL tumor suppressor gene, loss of chromosome 14q, which includes
HIF1A, and gain of chromosome 5q. The relevant target(s) on chromosome 5q is not known. Here, we show
that 5q amplification leads to overexpression of the SQSTM1 oncogene in ccRCC lines and tumors. Over-
expression of SQSTM1 in ccRCC lines promoted resistance to redox stress and increased soft agar growth,
while downregulation of SQSTM1 decreased resistance to redox stress, impaired cellular fitness, and
decreased tumor formation. Therefore, the selection pressure to amplify 5q in ccRCC is driven, at least partly,
by SQSTM1.INTRODUCTION
Kidney cancer is a common cancer in the developed world. The
most common form of kidney cancer is clear cell renal cell carci-
noma (ccRCC), which is usually linked to biallelic inactivation of
the VHL tumor suppressor gene located on chromosome 3p25
(Shen and Kaelin, 2012). Loss of chromosome 3p, which also
harbors the renal cancer suppressors PBRM1, BAP1, and
SETD2, is found in virtually all ccRCCs (Cancer Genome Atlas
Research Network, 2013; Dalgliesh et al., 2010; Guo et al.,Significance
Kidney cancer is one of the ten most common cancers in the
gene on chromosome 3p is the signature lesion in clear cell
form of kidney cancer, but is not sufficient to cause this dise
genetic events that cooperate with VHL loss to cause ccRCC
together with chromosome 3p loss, including some with un
arms. We show here that 5q copy number gains in renal canc
carcinogenesis.
738 Cancer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc.2011; Pen˜a-Llopis et al., 2012; Sato et al., 2013; Varela et al.,
2011). The VHL gene product (pVHL) targets the hypoxia-induc-
ible factor (HIF)a transcription factors for proteasomal degrada-
tion. Increased HIF2a promotes pVHL-defective tumorigenesis
(Kondo et al., 2003; Raval et al., 2005; Shen and Kaelin, 2012).
In addition to 3p loss, ccRCCs often harbor large deletions
of chromosome 14q (40% of cases) and copy number gains
of chromosome 5q (70% of cases) (Beroukhim et al., 2009;
Cancer Genome Atlas Research Network, 2013; Chen et al.,
2009; Dondeti et al., 2012; Hagenkord et al., 2011; Krill-Burgerdeveloped world. Inactivation of the VHL tumor suppressor
renal cell carcinoma (ccRCC), which is the most common
ase. Therefore, there is a pressing need to understand the
. Many ccRCCs bear additional copies of chromosome 5q,
balanced translocations involving these two chromosomal
er lead to SQSTM1 overexpression, which promotes renal
Figure 1. Amplification of 5q Genes in ccRCC
MLPA scores of selected 5q amplicon genes in the indicated cell lines normalized to HK-2 immortalized renal epithelial cells (diploid = 1). Gray bars indicate
control exons on chromosomes 1 and 17. Error bars indicate SD. See also Figure S1.
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SQSTM1 Is a Chromosome 5q Kidney Cancer Oncogeneet al., 2012; Sato et al., 2013; Shen et al., 2011). Loss of chromo-
some 14q and gain of chromosome 5q, considered either indi-
vidually or together, are seen more often in kidney cancer than
in other cancers and presumably reflect selection pressure to
silence one or more 14q kidney cancer suppressor genes and
to increase the expression of one or more 5q kidney cancer
oncogenes (Shen et al., 2011). It is interesting that unbalanced
translocations involving chromosomes 3p and 5q, including
constitutional translocations, have been reported in kidney
cancer that result in loss of chromosome 3p and gain of 5q
(Bos et al., 1998; Iqbal et al., 1996; Kenck et al., 1997; Kovacs
et al., 1987, 1991; Kovacs and Frisch, 1989; Kovacs and Kung,
1991; Presti et al., 1991).
HIF1a, which antagonizes HIF2a in certain settings, appears
to be a target of the 14q deletions (Shen et al., 2011), while the
relevant chromosome 5q gene(s) is/are unknown. We recently
used high-density SNP arrays to measure copy number changes
in 90 ccRCCs and 21 ccRCC cell lines (Beroukhim et al., 2009).
Approximately 70% of the samples exhibited increased copies
of a region of 5q with a peak at 5q35.3 that, allowing for possible
passenger events, contained about 61 genes (Beroukhim et al.,
2009). Notably, at least 12 of these genes were overexpressed
relative to nonamplified tumors (p < 0.05) including GNB2L1,
MGAT1, RUFY1, RNF130, MAPK9, CANX, CNOT6, SQSTM1,CaLTC4S, TBC1D9B, HNRPH1, and FLT4 (Beroukhim et al.,
2009). In this study, we sought to identify the 5q amplicon
gene underlying the selection pressure for 5q copy number gains
in ccRCC.
RESULTS
We interrogated the copy number changes in 16 ccRCC cell lines
using multiplex ligation-dependent probe amplification (MLPA)
of 12 randomly selected genes spanning the 5q amplicon (two
to four exons per gene) as well as three randomly selected
control exons located elsewhere in the genome. Two cell lines
(A498 and SLR21) did not exhibit 5q gains (MLPA score 1) rela-
tive to HK-2 immortalized renal epithelial cells (Ryan et al.,
1994), while the remaining 14 lines exhibited low-level copy
gains suggestive of three to six copies (MLPA score 1.5–3) of
5q relative to a diploid cell with two copies (MLPA score 1) (Fig-
ure 1; Figure S1 available online). These 5q copy numbers are
consistent with earlier cytogenetic and Southern blot studies of
ccRCCs (Kenck et al., 1997; Kovacs et al., 1991; Kovacs and
Frisch, 1989; Kovacs and Kung, 1991). Of note, the 5q gain in
one cell line (UMRC-6) appeared to be restricted to the telomeric
genes MGAT4B, SQSTM1, MAPK9, and GNB2L1, while the
other cell lines appeared, given the variability of the assay, toncer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc. 739
Figure 2. Amplification and Increased Expression of SQSTM1 in ccRCC
(A) Fold induction of mRNAs for genes located within the 5q amplicon in 5q-amplified ccRCC lines (Caki-2, UMRC-2, UMRC-6, and 769-P) relative to HK-2 cells.
Bubble sizes reflect mRNA abundance relative to ACTB mRNA in the 5q-amplified cells.
(B) MLPA scores of SQSTM1 (mean of eight exons) in the indicated cell lines normalized to HK-2 immortalized renal epithelial cells (diploid = 1). Error bars
indicate SD.
(C) SQSTM1 mRNA levels in the indicated cell lines, as determined by real-time PCR, relative to HK-2 cells.
(D) Anti-p62 immunoblot (IB) analysis of the indicated ccRCC cell lines. Loading was assessed by Ponceau S staining.
(E) SQSTM1mRNA levels as a function of SQSTM1 copy number in TCGA data set. Gain refers to samples with one inferred additional DNA copy. Amp refers to
samples withR2 inferred additional copies. RPKM, reads per kilobase per million reads. Black horizontal bar indicates the median.
(F and G) Box plots depicting correlation between p62 immunohistochemical staining, as determined by percentage of p62 positive cells (F) and p62 staining
intensity (G), in human ccRCC samples and tumor grade. Black horizontal bar indicates the median. Black x indicates the mean.
See also Figure S2 and Table S1.
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genes (Figures 1 and S1).
In parallel, we measured the mRNA levels of the 61 recurrently
amplified 5q genes by quantitative real-time PCR in four of the
5q amplified cancer cell lines analyzed earlier as well as in
HK-2 cells. As expected, multiple mRNAs were increased in
the four 5q amplified lines relative to HK-2 cells (Figure 2A; Table
S1). Three mRNAs were induced greater than 12-fold but were
of very low abundance (ADAMTS2, MSX2, and PCDH24). We
elected to study SQSTM1 further because SQSTM1 over-
expression was conspicuous when taking into account both740 Cancer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc.fold induction and absolute levels of the mRNA expression of
the 61 genes, and because SQSTM1 is known or suspected of
being an oncogene in other settings (Duran et al., 2008; Inami
et al., 2011; Mathew et al., 2009; Nezis and Stenmark, 2012;
Puissant et al., 2012).
SQSTM1 copy number was increased in every 5q amplified
cell line (Figures 2B and S2A) and was associated with increased
SQSTM1 mRNA levels, as determined by real-time PCR (Fig-
ure 2C) and northern blot analysis (Figure S2B), and protein
(p62) levels (Figure 2D), relative to HK-2 cells. Notably, SQSTM1
mRNA levels, and particularly p62 protein levels, were also
Figure 3. Activation of NRF2 in ccRCC
(A) Genomic alterations of NRF2, KEAP1, and SQSTM1 in TCGA data (Cancer Genome Atlas Research Network, 2013).
(B–D) GSEA of tumors with high SQSTM1 mRNA levels using gene sets associated with activation of NRF2 (B), response to oxidative stress (C), and mito-
chondrion organization and biogenesis (D).
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2D, and S2B). This suggests that A498 cells also upregulate p62
but through an alternative mechanism (discussed later).
Conversely, in 786-O and RCC4 cells, SQSTM1 mRNA and
protein levels reverted toward those seen in HK-2 cells, possibly
due to prolonged passage in culture (Figures 2C, 2D, and S2B).
Of note, SQSTM1 mRNA levels are increased in 5q-amplified
kidney tumors compared to nonamplified kidney tumors, or
normal kidney (Beroukhim et al., 2009; Cancer Genome Atlas
Research Network, 2013) (Figure 2E), indicating that SQSTM1
mRNA expression level is regulated at the gene copy number
level. However, SQSTM1 mRNA expression levels also showed
considerable variation that cannot be attributed to gene copy
number aberrations alone. Notably, increased levels of p62 are
associated with increased tumor grade in ccRCCs (Figures 2F,
2G, and S2C–S2F).
p62 inactivates kelch-like ECH-associated protein 1 (KEAP1),
which is a negative regulator of nuclear factor erythroid 2-
related factor 2 (NRF2) (Nezis and Stenmark, 2012; Puissant
et al., 2012). Conversely, NRF2 can activate expression of
SQSTM1 (Jain et al., 2010). It is interesting that deregulationCaof NRF2, which is a master regulator of the antioxidant
response, plays an important role in papillary renal carcinoma
as well as other tumors (Adam et al., 2011; Hayes and McMa-
hon, 2009; Ooi et al., 2011). Moreover, NRF2 (official name
NFE2L2) and KEAP1 mutations have been detected, albeit
infrequently, in ccRCC (Figure 3A) (Cancer Genome Atlas
Research Network, 2013; Sato et al., 2013). The NRF2 gene
had inferred somatic mutations in 5 of 368 cases and high-level
DNA amplification in two additional cases. The KEAP1 gene
had somatic missense mutations in three cases and a homozy-
gous deletion in one additional case (Figure 3A). Notably, the
NRF2 missense mutations would be predicted to disrupt
KEAP1 binding and to thereby activate NRF2. Of note, NRF2
mutations, KEAP1 mutations, and high-level SQSTM1 amplifi-
cation (gain of two or more copies) appear to be mutually
exclusive.
We did not observe a strong NRF2 transcriptional signature in
5q-amplified tumors relative to nonamplified tumors by gene set
enrichment analysis (GSEA; data not shown), possibly because
changes in SQSTM1 mRNA levels cannot be attributed to copy
number aberrations alone or because nonamplified tumors canncer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc. 741
Figure 4. Increased Expression of SQSTM1 in ccRCC Confers Resistance to Redox Stress
(A) Immunoblot (IB) analysis of the indicated cell lines. Equal loading was confirmed by Ponceau S staining of whole cell extracts (WCE) used for p62 and KEAP1
analysis and nuclear extracts (NE) used for NRF2 analysis.
(B) Normalized absorbance at 570 nm (A570) and representative images of the cell lines in (A) after treatment with increasing amounts of H2O2 for 4 hr followed by
staining with crystal violet 3 days later. For each cell line, the absorbance values for solubilized crystal violet were normalized based on cells that were not
exposed to H2O2. Error bars indicate SD.
(C and D) Immunoblot analysis (C), normalized absorbance (A570), and representative images of crystal violet staining (D) of 786-O and RCC4 cells infected with a
lentivirus expressing SQSTM1 with a C-terminal V5 epitope tag or with the empty viral vector. Absorbance values were normalized as in (B). Error bars indicate
SD. *p < 0.05 compared to vector cells.
(E and F) Immunoblot analysis (E), normalized absorbance (A570), and representative images of crystal violet staining (F) of UMRC-2 and UMRC-6 cells infected
with lentiviruses expressing SQSTM1 shRNAs or a nontargeting control shRNA. 786-O, A498, SLR21, and HK-2 cells were included in (E) for comparison.
Absorbance values were normalized as in (B). Error bars indicate SD. *p < 0.05 compared to control shRNA.
See also Figure S3.
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respect to the former possibility, we reasoned that we could
more directly probe the function of SQSTM1 in The Cancer
Genome Atlas (TCGA) data by correlating gene set expression
with SQSTM1 mRNA expression levels. Indeed, we found that
human ccRCCs with high levels of SQSTM1 mRNA exhibit
transcriptional profiles that are consistent with activation of
NRF2, as determined by GSEA using gene sets consisting of
previously annotated NRF2 target genes (Figure 3B) and gene
sets linked to NRF2-regulated processes, such as response to
oxidative stress and mitochondrial biosynthesis (Figures 3C
and 3D).
The sensitivity of ccRCC cell lines to oxidative stress mirrored
their basal p62 levels and, particularly, their NRF2 levels (Figures
4A and 4B). A498 cells displayed high basal levels of NRF2
and modestly elevated p62 levels, suggesting that these cells
harbor a mutation that drives the production of NRF2, which
secondarily induces p62. SLR21 cells also displayed high742 Cancer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc.NRF2 levels, possibly due to low levels of KEAP1. NRF2 and
KEAP1 themselves, however, appear to be wild-type in A498
and SLR21 cells based on cDNA sequencing (data not shown).
Exogenous expression of p62 in cells with low basal p62 levels
induced NRF2 and reduced sensitivity to oxidative stress (Fig-
ures 4C, 4D, and S3A). Conversely, knockdown of p62 with three
distinct shRNAs reduced NRF2 levels and increased reactive
oxygen species (ROS) sensitivity (Figures 4E, 4F, S3B, and
S3C). Collectively, these results support that 5q copy number
gains in ccRCC increase p62 levels, which activate NRF2 and
confer resistance to oxidative stress.
Acute VHL loss can induce senescence mediated, at least
partly, by oxidative stress (Welford et al., 2010; Young et al.,
2008), suggesting that p62 overexpression and VHL loss might
cooperate with one another to promote renal carcinogenesis.
In keeping with this view, we found that three independent
SQSTM1 shRNAs, but not a control shRNA, impaired the ability
of the 5q-amplified VHL/ ccRCC cell line UMRC-2 to grow in
Figure 5. Downregulation of SQSTM1 Inhibits ccRCC Growth
(A) Soft agar assay of parental UMRC-2 cells or cells infected with lentiviruses expressing SQSTM1 shRNAs or a nontargeting control shRNA. Scale bars, 0.5 mm.
(B) Immunoblot (IB) analysis of UMRC-2 cells infected with a virus encoding firefly luciferase and then with lentiviruses expressing a doxycycline (DOX)-inducible
SQSTM1 shRNA (TetOn-shSQSTM1) or a control LacZ shRNA (TetOn-shLacZ). 786-O, A498, SLR21, and HK-2 cells were included for comparison.
(C and D) Orthotopic tumor growth by cells in (B) as determined by bioluminescent imaging (C) and total renal mass at necropsy (week 7) (D). Both kidneys of NOD
scid gamma mice were injected with 2 3 106 viable tumor cells (LacZ shRNA cells in one kidney and SQSTM1 shRNA cells in the other). Following successful
tumor engraftment, as determined by serial bioluminescent imaging, mice were begun on chow containing doxycycline (day 0). The ratio of SQSTM1 shRNA
tumor photons to LacZ shRNA tumor photons was measured weekly and normalized to day 0. Error bars indicate SEM.
(E–G) Immunoblot analysis (E), representative soft agar colonies (F), and soft agar colony quantification (G) of UMRC-2 cells infected with lentiviruses expressing
a doxycycline (DOX)-inducible SQSTM1 shRNA (TetOn-shSQSTM1) or a control LacZ shRNA (TetOn-shLacZ) and later infected with a lentivirus expressing an
shRNA-resistant SQSTM1 cDNA (SQSTM1-r) or the empty vector. Scale bars, 0.5 mm. Error bars indicate SD. *p < 0.05.
(H) Orthotopic tumor growth of UMRC-2 cells expressing a doxycycline (DOX)-inducible SQSTM1 shRNA (TetOn-shSQSTM1) and subsequently infected with a
lentivirus expressing an shRNA-resistant SQSTM1 cDNA (SQSTM1-r) or the vector, as in (E), as determined by total renalmass at necropsy (week 6). Both kidneys
of NOD scid gamma mice were injected with 1.53 106 viable tumor cells (SQSTM1-r cells in one kidney and vector cells in the other). Mice were begun on chow
containing doxycycline 10 days later. Error bars indicate SEM.
See also Figure S4.
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SQSTM1 Is a Chromosome 5q Kidney Cancer Oncogenesoft agar (Figure 5A; Figure S4A). The same SQSTM1 shRNAs
had only minimal effects on soft agar growth by 293 human
embyronic kidney cells, which have low basal levels of p62
(Figures S4B–S4D). Induction of a SQSTM1 shRNA, but not a
control shRNA, also decreased tumor formation by UMRC-2
cells (Figures 5B–5D) and UMRC-6 cells (Figures S4E and
S4F). These phenotypic effects were specifically due to loss of
p62 because they were reversed with a lentivirus encoding an
shRNA-resistant SQSTM1 mRNA (Figures 5E–5H).
The finding that p62 downregulation impaired ccRCC growth
could simply indicate that SQSTM1 is a housekeeping gene
and does not necessarily imply that supraphysiological levelsCaof p62 promote tumor growth. Indeed, in parallel studies, we
infected multiple ccRCC cell lines with a custom shRNA library
targeting all 61 5q amplicon genes (three to ten shRNAs
per gene), monitored shRNA abundance over time by deep
sequencing, and scored shRNA depletion/enrichment for each
gene using the RNAi gene enrichment ranking algorithm (Luo
et al., 2008). We also evaluated the effects of shRNA-mediated
loss of the 61 individual 5q genes on cellular fitness in a different
experimental format wherein cells expressing red fluorescent
protein and an effective shRNA targeting the 5q gene of interest
were cocultured with cells expressing Venus fluorescent protein
and a control shRNA and monitored by fluorescence-activatedncer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc. 743
Figure 6. SQSTM1 Is a Renal Cancer Oncogene
(A and B) Immunoblot (IB) analysis (A) and proliferation curves (B) of A498 cells infected with lentiviruses expressing SQSTM1 or LacZ, each with a C-terminal V5
epitope tag, or with the empty viral vector. Error bars indicate SD.
(C and D) Immunoblot analysis (C) and proliferation curves (D) of 786-O cells infected with a lentivirus expressing SQSTM1 or with the empty viral vector. UMRC-2
cells were included in (C) for comparison. Error bars indicate SD.
(E) Soft agar assay of A498 cells analyzed in (A). Scale bars, 0.5 mm.
(F and G) Immunoblot analysis (F) and soft agar assay (G) of A498 cells infected with increasing amounts, as indicated by the triangle, of a lentivirus expressing
SQSTM1 with a C-terminal V5 epitope tag or with the empty viral vector. UMRC-2 cells were included in (F) for comparison. Scale bars, 0.5 mm.
(H) Orthotopic tumor growth of 786-O cells analyzed in (C), as determined by total renal mass at necropsy (week 8). Both kidneys of Swiss nudemicewere injected
with 1 3 106 viable tumor cells (SQSTM1 cells in one kidney and vector cells in the other). Error bars indicate SEM.
See also Figure S5.
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in addition to SQSTM1, decreased the fitness of ccRCC cell lines
(Figures S4G–S4J). Although some of these genes might be
oncogenes, it is more likely that many of them are passenger
housekeeping genes.
We therefore askedwhether increased expression ofSQSTM1
promotes ccRCC growth. Lentiviral expression of SQSTM1 in
A498 and 786-O cells did not affect proliferation under standard
cell culture conditions (Figures 6A–6D; Figures S5A and S5B) but
promoted soft agar growth (Figures 6E–6G and S5C) and tumor
formation in vivo (Figure 6H). These results were specific
because the same vector did not affect UMRC-2 cells, which
have high endogenous levels of p62 (Figures S5D and S5E). In
addition, the SQSTM1 shRNAs that we documented impaired
ccRCC fitness and tumor growth (Figures 4, 5, and S4) did so
without lowering p62 levels below those seen in HK-2, 786-O,
and SLR21 cells (Figures 4E, 5B, S3C, and S4E). Collectively,
these results argue that supraphysiological p62 levels promote
renal tumorigenesis.744 Cancer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc.p62 is a multifunctional protein with multiple subdomains that
interact with a variety of downstream effector molecules
(Figure 7A) (Geetha and Wooten, 2002; Moscat and Diaz-
Meco, 2009; Nezis and Stenmark, 2012; Puissant et al., 2012).
We found that a previously described p62 mutant (‘‘CT’’) (Duran
et al., 2011) lacking amino acids 1–229—and, hence, lacking
both its PB1 (Phox/Bem1p) and ZZ (central zinc finger) domains
as well as part of its TBS (TRAF6-binding) domain—failed to
promote soft agar growth in A498 cells (Figures 7A–7C) and
did not rescue soft agar growth in UMRC-2 cells that were
depleted of endogenous p62 with an inducible shRNA, despite
retaining the ability to induce NRF2 (Figures 7D–7F and S6).
Therefore, promotion of soft agar growth by p62 requires certain
functions mediated by its N terminus. On the other hand, a p62
variant (‘‘m6A’’) bearing an inactivating mutation within its
KEAP1-binding domain—and, hence, unable to induce NRF2—
retained the ability to promote soft agar growth in A498 cells
and could rescue UMRC-2 cells lacking endogenous p62
(Komatsu et al., 2010) (Figures 7A–7F and S6). Moreover,
Figure 7. Promotion of Soft Agar Growth and Activation of NRF2 Are Dissociable Activities of p62
(A) Schematic of p62. SQSTM1-CT mutant lacks the N-terminal 229 amino acids. SQSTM1-m6A replaces residues 347–352 with alanines. PB1, Phox/Bem1p
domain; ZZ, central zinc finger domain; TBS, TRAF6-binding domain; PEST, proline (P), glutamic acid (E), serine (S), and threonine (T)-rich domain; LIR, LC3
interaction region; UBA, ubiquitin-associated domain.
(B and C) Immunoblot (IB) analysis (B) and soft agar assay (C) of A498 cells infected with lentiviruses expressing wild-type SQSTM1 or mutant SQSTM1 (CT or
m6A) or with the empty viral vector. Scale bars, 0.5 mm.
(D–F) Immunoblot analysis (D), representative soft agar colonies (E) and soft agar colony quantification (F) of UMRC-2 cells infected with lentiviruses expressing a
doxycycline (DOX)-inducible SQSTM1 shRNA (TetOn-shSQSTM1) or a control LacZ shRNA (TetOn-shLacZ) and later infected with lentiviruses expressing an
shRNA-resistant wild-type SQSTM1 cDNA (SQSTM1-r) or mutant SQSTM1 cDNA (CT-r or m6A-r), or with the empty viral vector. Scale bars, 0.5 mm. Error bars
indicate SD. *p < 0.05.
See also Figure S6.
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of exogenous p62, as noted earlier. These two observations
suggested that promotion of soft agar growth by p62 involves
at least one effector other than NRF2.
It has been reported that wild-type p62, but not p62 CT, can
activate mammalian target of rapamycin (mTOR) (Duran et al.,
2011). In addition, we found that activation of mTOR by Rheb2
or a constitutively active RagB mutant (RagBGTP), like over-
expression of p62 itself, enhances the soft agar growth of
A498 cells (Figures S7A–S7C). Moreover, some ccRCCs harbor
mutations, such as TSC2 or MTOR mutations, that activate the
mTOR pathway, and such mutations, like NRF2 pathway muta-
tions, are enriched in tumors that do not have high-level chromo-
some 5q copy number gains, suggesting that p62 provides an
alternative mechanism to activate mTOR (Cancer Genome Atlas
Research Network, 2013). Although overexpression of p62 in
ccRCC cells did not consistently activate mTOR under any
condition tested (data not shown), we did observe that acute
siRNA-mediated knockdown of p62 attenuated mTOR signalingCa(Figure S7D). Moreover, activation of mTORwith Rheb2 restored
soft agar growth in UMRC-2 cells depleted of p62 (Figures 8A
and 8B). Conversely, pharmacological blockade of mTOR with
1 nM rapamycin prevented soft agar growth driven by p62 or
Rheb2 (Figure 8C). Therefore, mTOR acts downstream or paral-
lel of p62.
DISCUSSION
Chromosome 5q is the region of the genome most frequently
amplified in ccRCC, and copy number changes involving
chromosome 5q are more common in ccRCC than in any other
cancer (Beroukhim et al., 2009; Chen et al., 2009; Dondeti
et al., 2012; Hagenkord et al., 2011; Krill-Burger et al., 2012;
Moore et al., 2012; Shen et al., 2011). Indeed, the triad of
chromosome 3p loss, chromosome 14q loss, and chromosome
5q gain is a signature abnormality in ccRCC. Our studies strongly
suggest that SQSTM1 is one of the genes underlying the recur-
rent 5q copy number gains in ccRCC.ncer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc. 745
Figure 8. mTOR Acts Downstream or Parallel of p62
(A andB) Immunoblot (IB) analysis (A) andsoft agar assay (B)ofUMRC-2cells infectedwith lentiviruses expressingadoxycycline (DOX)-inducibleSQSTM1shRNAor
a control LacZ shRNAand later infectedwith lentiviruses expressing enhancedgreen fluorescent protein (EGFP) or EGFP-Rheb2 fusion protein. Scale bars, 0.5mm.
(C) Soft agar assay of A498 cells infected with lentiviruses expressing an empty vector or SQSTM1 or cells infected with lentiviruses encoding EGFP or EGFP-
Rheb2. Cells were treated with either vehicle (DMSO) or rapamycin (1 nM). Scale bars, 0.5 mm.
(D) Signal transduction network involving p62 and kidney cancer mutational targets. Oncoproteins are shown in green, and tumor suppressors are shown in red.
For simplicity, not every possible link is shown. PI3K, phosphoinositide 3-kinase; TSC, complex formed by tuberin and hamartin, which are mutated in tuberous
sclerosis complex; mTOR =mammalian target of rapamycin; VHL, von Hippel-Lindau; REDD1, regulated in development and DNA damage responses 1; CARD9,
caspase recruitment domain containing protein 9; BNIP3, BCL2/adenovirus E1B 19 kDa interacting protein 3; KEAP1, kelch-like ECH-associated protein 1;
NRF2, nuclear factor erythroid 2-related factor 2; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells. FH, fumarate hydratase.
See also Figure S7.
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SQSTM1 Is a Chromosome 5q Kidney Cancer OncogeneSQSTM1 has been implicated as a potential oncogene in other
settings, including human hepatocelluar carcinomas, lung
carcinomas, pancreatic carcinomas, breast carcinomas, and in
immortalized baby mouse kidney cells (Duran et al., 2008; Inami
et al., 2011; Inoue et al., 2012; Mathew et al., 2009; Rolland et al.,
2007; Thompson et al., 2003). The SQSTM1 gene product, p62,
is a multifunctional protein that serves as an adaptor molecule to
facilitate the degradation of specific proteins by autophagy
(Geetha andWooten, 2002; Moscat and Diaz-Meco, 2009; Nezis
and Stenmark, 2012; Puissant et al., 2012). Of note, VHL/
ccRCC have high basal rates of autophagy (Bray et al., 2012).
The p62 protein also physically interacts with a number of
signalingmolecules to enhance the activity of downstream effec-
tors such as NRF2, NF-kB, and mTOR. For example, p62 can
bind to KEAP1 and prevent it from targeting NRF2 for degrada-
tion. There is increasing genetic and functional evidence that
NRF2, which activates a transcriptional program that promotes
resistance to redox stress, can promote tumor growth in some746 Cancer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc.settings (DeNicola et al., 2011; Hayes and McMahon, 2009;
Sporn and Liby, 2012). Acute VHL loss can, at least in some cells,
cause senescence that is due, at least partly, to oxidative stress
(Welford et al., 2010; Young et al., 2008). p62 might mitigate this
effect as well as contribute to the resistance of ccRCCs to
conventional cytotoxic therapy. Of note, SQSTM1 is itself an
NRF2 target gene and, hence, potentially capable of partici-
pating in a positive feedback loop (Jain et al., 2010). This might
contribute to the disproportionate increase in SQSTM1 mRNA
levels relative to the other 5q amplicon genes observed in
ccRCCs that have amplified chromosome 5q.
NRF2 pathway mutations occur, albeit rarely, in ccRCC
(Cancer Genome Atlas Research Network, 2013; Sato et al.,
2013) and, as shown here, are mutually exclusive with higher
level SQSTM1 amplification (gain of two or more copies), further
suggesting that NRF2 is likely an important target of p62 in
ccRCC. On the other hand, we found that the KEAP1-binding
domain of p62 was neither necessary nor sufficient for p62 to
Cancer Cell
SQSTM1 Is a Chromosome 5q Kidney Cancer Oncogenepromote renal transformation, as measured in soft agar assays,
indicating that additional p62 targets play roles in renal carcino-
genesis. p62 also binds to several proteins upstream of NF-kB,
including atypical PKC members and TRAF6, leading to en-
hanced NF-kB activity in certain settings (Nakamura et al.,
2010; Nezis and Stenmark, 2012; Puissant et al., 2012). It is inter-
esting that pVHL binds to and inhibits atypical PKC members
and, through several mechanisms, suppresses NF-kB activity
(An et al., 2005; An and Rettig, 2005; Datta et al., 2000, 2001;
Lee et al., 2005; Okuda et al., 1999, 2001; Pantuck et al., 2010;
Schermer et al., 2006; Yang et al., 2007). NF-kB promotes
VHL/ ccRCC growth in vivo (An et al., 2005; An and Rettig,
2005; Pantuck et al., 2010; Yang et al., 2007). Moreover, a recent
report suggested that p62 binds to the Raptor complex and
accentuates mTOR signaling under some experimental condi-
tions (Duran et al., 2011). A significant fraction of ccRCCs have
mutations that directly or indirectly activatemTOR, andwe found
that forced activation of mTOR rescues soft agar growth in p62-
depleted ccRCC cells, indicating that mTOR acts downstream or
parallel of p62 (Cancer Genome Atlas Research Network, 2013).
As was true for NRF2, mTOR pathway mutations are mutually
exclusive of high-level chromosome 5q gains in ccRCC (Cancer
Genome Atlas Research Network, 2013). Several nonmutually
exclusive explanations might account for this observation. First,
as indicated earlier, p62 might enhance mTOR activity and
decrease the selection pressure to mutate the mTOR pathway.
Second, mTOR activation inhibits autophagy. This promotes
the accumulation of p62 by preventing p62 from being destroyed
together with its autophagocytic cargo. Therefore, mTOR activa-
tion might decrease the selection pressure to increase SQSTM1
copy number. Finally, it is possible that p62 and mTOR operate
on parallel, but redundant, pathways to promote renal carcino-
genesis. Of note, a recent study showed that NRF2 activation
in lung cancer cells renders them mTOR dependent (Shibata
et al., 2010).
mTOR is a validated therapeutic target in ccRCC. Notably,
VHL/ ccRCC cells are more sensitive than their pVHL-
proficient counterparts to drugs, such as mTOR inhibitors,
that promote autophagy (Hudes et al., 2007; Thomas et al.,
2006; Turcotte et al., 2008). Moreover, a recent study showed
that murine tumors linked to Tsc2 mutations—and, hence,
mTOR activation—are p62 dependent (Parkhitko et al., 2011).
The relationship between mTOR inhibition, induction of auto-
phagy, and suppression of ccRCC is likely to be complex,
however. In some preclinical models, blocking autophagy
actually enhances the activity of mTOR inhibitors by increasing
mitochondrial ROS production in the face of impaired NRF2
activity stemming from the effects of mTOR on NRF2 nuclear
localization (Bray et al., 2012). It will be important to ask whether
the therapeutic efficacy of mTOR inhibitors is due, at least partly,
to downregulation of p62 and, if so, whether p62 levels can be
used as predictive or pharmocodynamic biomarkers.
Although SQSTM1 appears to be an important driver on
chromosome 5q, the chromosomal gains and losses in renal
cancer, including 5q gains, are nonfocal, suggesting that they
are driven by more than one gene. Indeed, 3p loss targets
several ccRCC suppressor genes. In this regard, the 5q ampli-
con contains a number of other genes that could plausibly act
as renal cancer oncogenes, including MAML1, FGFR4, andCaMAPK9. These genes, however, did not consistently score in
the oncogene assays described here. For example, FGFR4
shRNAs impaired cell fitness in vitro (Figure S4J) but promoted
orthotopic tumor growth (data not shown). GNB2L1/RACK1
was, together with SQSTM1, recently highlighted as a potential
ccRCC 5q oncogene because its protein product, like p62,
activates mTOR (Duran et al., 2011; He et al., 2011) and because
high-level 5q amplification is, as stated earlier, mutually
exclusive with mTOR pathway mutations in ccRCC (Cancer
Genome Atlas Research Network, 2013). Nonetheless,
GNB2L1/RACK1 did not score as an oncogene in our assays
(Figures S4G and S4I). It remains possible, however, that some
of these genes confer a growth advantage under conditions
that are not replicated by our assays. Knockdown of the 5q
amplicon gene STC2 impaired ccRCC fitness in our hands
(Figure S4J) and in a recent report (Dondeti et al., 2012). Whether
STC2 is a housekeeping gene or an oncogene warrants further
study.
In summary, enhanced expression ofSQSTM1 promotes renal
carcinogenesis in vitro and in vivo. The SQSTM1 gene product,
p62, regulates NRF2, NF-kB, and mTOR, all three of which
network with known renal carcinoma suppressor genes such
as VHL, FH, TSC1, and TSC2 (Figure 8D). It will be important
to determine which p62 effector pathways contribute to renal
carcinogenesis and whether they can be pharmacologically
attacked.
EXPERIMENTAL PROCEDURES
Immunohistochemistry
All ccRCC samples were obtained with patients’ consent to an institutional
review board-approved protocol for data and tissue collection to use for
clinical research (DFCI #01-130). Detailed procedures are described in the
matching section of Supplemental Experimental Procedures.
Cell Lines
A498, A704, Caki-2, HK-2, RCC4, 769-P, and 786-O cells were purchased
from the American Type Culture Collection. UMRC-2, UMRC-6, and
UOK101 cells were provided by Drs. Bert Zbar and Martson Linehan (National
Cancer Institute). SK-RC-20 cells were provided by Drs. Gerd Ritter and
Beatrice Yin (Memorial Sloan-Kettering Cancer Center). SLR20, SLR21,
SLR23, SLR24, SLR25, and SLR26 cells were supplied by Drs. Mark A. Rubin
and Kirsten Mertz (Weill Cornell Medical College). HK-2 cells, which are prox-
imal renal tubular cells immortalized with human papilloma virus E6 and E7
proteins (Ryan et al., 1994), were maintained in keratinocyte serum-free
medium supplemented with 0.05 mg/ml of bovine pituitary extract and
5 ng/ml of human recombinant epidermal growth factor (Invitrogen). A498,
RCC4, UMRC-2, UMRC-6, UOK101, and 786-O cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine
serum (FBS); 769-P, SLR20, SLR21, SLR23, SLR24, SLR25, and SLR26 cells
were maintained in RPMI-1640 containing 10% FBS; A704 cells were main-
tained in Eagle’s minimum essential medium (Lonza12-662) supplemented
with 2 mM L-glutamine and 15% FBS; SK-RC-20 cells were maintained in
RPMI-1640 containing 10% FBS and nonessential amino acids (Invitrogen),
and Caki-2 cells were maintained in McCoy’s 5A containing 10% FBS.
Following lentivirus infection, cells weremaintained in the presence of puromy-
cin (2 mg/ml) or blasticidin (10 mg/ml), depending on the vector. All cells were
kept at 37C in 5% CO2. VHL genotypes for the renal cancer cell lines used
in this study are listed in the matching section of Supplemental Experimental
Procedures.
Plasmids
pLenti6/V5-DEST and pLenti6/V5-GW-LacZ were purchased from Invitrogen.
The SQSTM1 cDNA is a generous gift from Dr. Eileen White (The Cancerncer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc. 747
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SQSTM1 Is a Chromosome 5q Kidney Cancer OncogeneInstitute of New Jersey) and was subcloned between the SpeI and XhoI sites in
pLenti6/V5-DEST using the following primers: SQSTM1_For 50-actgtcac
tagtgccaccatggcgtcgctcaccgtgaaggcc-30 and SQSTM1_Rev 50-atcacctc
gaggccaacggcgggggatgctttg-30. pLenti6/V5-SQSTM1-CT was generated
using SQSTM1_Rev and the following forward primer: SQSTM1-CT_For 50-
actgtcactagtgccaccatggaggatccgagtgtg-30. pLenti6/V5-SQSTM1-m6A was
generated by site-directed mutagenesis using the following primers:
SQSTM1-m_For 50atctgtcttcaaaagaagtggccgcggctgcagctgcactccagtccctac
agatgccag-30 and SQSTM1-m_Rev 50ctggcatctgtagggactggagtgcagctgc
agccgcggccacttcttttgaagacagat-30. pLenti6/V5-SQSTM1-r was generated
by site-directed mutagenesis using the following primers: SQSTM1-r_For 50-
gccacgcagtctctggcggaacaaatgaggaaaattgcattggagtccgaggggcgccct-30 and
SQSTM1-r_Rev 50-agggcgcccctcggactccaatgcaattttcctcatttgttccgccagaga
ctgcgtggc-30. SQSTM1-CT-r was generated using SQSTM1-r as the template
and primers of SQSTM1-CT_For and SQSTM1_Rev. SQSTM1-m6A-r was
generated by two-step PCR. First, the 50 fragment and the 30 fragment were
amplified using SQSTM1-r as the template and the following primer pairs,
respectively: SQSTM1_For with SQSTM1-m_Rev and SQSTM1-m_For with
SQSTM1_Rev. The 50 fragment and the 30 fragment were then mixed and
amplified using primers SQSTM1_For and SQSTM1_Rev. pLKO-SQSTM1-
7234, -7235, -7236, and -7237 were obtained from the RNAi Consortium
collection. For doxycycline-inducible shRNA expression, oligos for the corre-
sponding shRNAs (SQSTM1-7235) were annealed and subcloned between the
AgeI and EcoRI sites in pLKO-TetOn (Addgene). All plasmids were verified
by DNA sequencing. pLJM1-EGFP, pLJM1-EGFP-Rheb2, pLJM1-Flag-
RagBGTP, and pLJM1-Flag-Metap2 are generous gifts fromDr. DavidM. Saba-
tini (Whitehead Institute for Biomedical Research).
MLPA
MLPA was performed as described elsewhere (Kozlowski et al., 2007; Shen
et al., 2011), using reagents provided by MRC-Holland (http://www.mlpa.
com). The probe sets are listed in the matching section in the Supplemental
Experimental Procedures. The capillary electrophoresis and peak height
determination of amplification products were performed by Mei Lin at the
DNA Sequencing Facility, Brigham and Women’s Hospital. Briefly, amplifica-
tion products were 103 diluted in Hi-Di Formamide (ABI) containing 1/16
volume of ROX500 size standard (ABI) and then were separated by size on
an ABI 3100 Genetic Analyzer. Electropherograms were analyzed by Gene-
Mapper v3.5 (ABI), and peak height data were exported to an Excel table.
Sensitivity to H2O2
Cells were plated on 24-well plates in triplicates or quadruplicates. Cells were
washed twice with PBS and incubated for 4 hr in DMEM without pyruvate
(Invitrogen) supplemented with 1%FBS containing H2O2 at the concentrations
indicated in the figures. The media were then changed to complete growth
medium appropriate for individual cell lines for 3 to 4 days prior to fixation
and staining with crystal violet (4 mg/ml). To measure the relative density of
cells, crystal violet was solubilized with 1% SDS and absorbance was
measured at 570 nm. Each experiment was repeated at least three times. Re-
sults were evaluated using a two-sided student t test.
Orthotopic Xenograft and Bioluminescent Imaging
Immunodeficient mice were obtained from Taconic (Swiss nude mice) or The
Jackson Laboratory (NOD scid gamma mice). Orthotopic xenograft was
performed essentially as described elsewhere (Li et al., 2007). Briefly, after
the kidney was exposed, 1 to 23 106 viable cells were injected near the lower
pole into the renal parenchyma. Tumors were monitored by palpation or by
bioluminescent imaging. Bioluminescent detection and quantification of tumor
burden were performed as described elsewhere (Zhang et al., 2009). For each
mouse, total photons from the kidney injected with cells expressing SQSTM1
shRNA were divided by total photons from the kidney injected with cells
expressing LacZ shRNA and normalized to the ratio for that mouse on the
day starting chow containing doxycycline (6 g doxycycline/1 kg chow; Bio-
serv). Mice were sacrificed 6 to 8 weeks after injection, as specified in the
figure legends. Total masses of kidney and tumor are presented as mean ±
SEM and evaluated statistically using a t test. All animal experiments complied
with National Institutes of Health guidelines and were approved by the Dana-
Farber Cancer Institute Animal Care and Use Committee.748 Cancer Cell 24, 738–750, December 9, 2013 ª2013 Elsevier Inc.TCGA Data
mRNA expression and DNA copy number data were obtained for the TCGA
kidney renal clear cell carcinoma project through the cBio cancer genomics
portal (http://www.cbioportal.org/public-portal/) (Cerami et al., 2012). We
used the ‘‘core freeze’’ set of samples, which had all types of data available
for all samples (n = 368). We used log-transformed RPKM (reads per kilobase
per million reads) values for mRNA expression, and DNA copy number sum-
marized at the gene level by the GISTIC algorithm (Mermel et al., 2011).
GSEA
We used GSEA (Subramanian et al., 2005) to identify pathways and gene sets
associated with variation in SQSTM1 mRNA expression levels across TCGA
tumor samples. Genes were sorted by their concordance (Pearson correlation)
with SQSTM1mRNA expression levels across tumors, and GSEA was used to
evaluate gene sets enriched for either negatively or positively correlated
genes. All genes on chromosome 5q were excluded from the analysis to avoid
bias in the analysis related to the frequent broad copy number gains of chro-
mosome 5q. All curated gene sets (MSigDB c2 collection) of size 5–500 genes
(n = 3,173 gene sets) were evaluated for enrichment. To account for gene-gene
correlations in the enrichment analysis, GSEA p values were computed with
respect to a null distribution obtained from 1,000 randomizations of the
patient-phenotype labels.
NRF2 Target Gene Sets
We compiled two distinct NRF2 target gene sets based on previous studies
of NRF2 function. The first set comprised a group of genes (n = 82) showing
high-confidence NRF2 binding sites in chromatin immunoprecipitation
sequencing experiments and expression downregulation (log2 expression
change > 0.15) in NRF2 silenced cell lines (Chorley et al., 2012). The second
set of genes (n = 89) corresponded to a curated list of target genes summa-
rized from multiple studies of NRF2 function (Hayes and McMahon, 2009).
The two gene sets, listed in the matching section in the Supplemental Exper-
imental Procedures, only showed moderate overlap (n = 11), and we used the
union (n = 160) of the two gene sets for GSEA. The GSEA data can be found at
http://cbio.mskcc.org/ajac/sqstm1/gsea/sqstm1_expr/.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.10.025.
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